Donald L. Hagan LLC’s Oramed Pharmaceuticals ORMP Stock Holding History

Donald L. Hagan LLC’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,000	Closed	-$7K	–	238
2016 Q1	$7K	Buy	+1,000	New	+$6.7K	0.01%	295
2015 Q4	–	Sell	-1,000	Closed	-$5K	–	239
2015 Q3	$5K	Buy	+1,000	New	+$6.29K	﹤0.01%	324

Other funds holding ORMP

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

FANJ

Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return

Donald L. Hagan LLC's ORMP Position: Q2 2016 in Review

Donald L. Hagan LLC sold out of Oramed Pharmaceuticals (ORMP) in Q2 2016, closing a stake of 1,000 shares — an estimated $7K sold.

Donald L. Hagan LLC first reported a position in ORMP in Q3 2015 and held it in 2 quarters. The position peaked at $7K in Q1 2016. 25 funds tracked by Wall St. Rank hold ORMP as of Q2 2016.

Donald L. Hagan LLC reported no remaining Oramed Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Donald L. Hagan LLC sold 1,000 Oramed Pharmaceuticals shares in Q2 2016, an estimated $7K.
Donald L. Hagan LLC first reported a position in Oramed Pharmaceuticals in Q3 2015 and held it in 2 quarters.
Donald L. Hagan LLC's Oramed Pharmaceuticals position peaked at $7K in Q1 2016.
25 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2016.

Based on Donald L. Hagan LLC's 13F filing for Q2 2016, filed 21 Jul 2016.